Category: Aggregate Spend Reporting

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

The Significance of Context in CMS Reporting

Regulator visitors to this blog will know how important it is for qordata to get facts about pharmaceutical spend data right. We would go so far as to say that protecting the sanctity, validity, and relevance of this data has a sacred status with us. But before data can be all this, it needs to […]

Instant Insights From CMS Open Payments Data 2016

People seeking to spend data on a specific physician will be searching through more than 600,000 physicians and/or going through 1,100 teaching hospital records with the latest update CMS makes in its Open Payments Database. At qordata, we have employed our data engineering chops to make your life just that much easier. This is the […]

qordata Leverages Its Analytics Capabilities To Uncover Critical Insights

CMS open payments reporting solution, qordata’s foremost solution for pharmaceutical spend analytics, helps drug and device manufacturers gain visibility into their spend data. With the publication of 2016 records by CMS on 30th June 2017, qordata has been amongst the first to share the industry’s most incisive insights in this blog. Data from 2016’s records […]

Pharma Associations and Transparency in Germany

In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, How to “Determine the Relationships of Different Global Disclosure Requirements,” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private-sector synergy. Or […]

The Impact of Pharma Disclosure on Public Healthcare

The synergy between pharma associations may never materialize. It may even backfire. We will elaborate on this in an upcoming post, with the real-life case of pharma disclosure in Germany. Today, we discuss how public interest has surfaced as a surprisingly powerful ally in the pharma transparency movement.  Before exploring the ‘whats’ and ‘hows’, we […]

7 Tips for Starting Your Pharma Analytics Program

In one of our most effective webinars this year, Wendy Derosa and Bryan Timer, both Compliance professionals at Merck USA, had useful advice for small and mid-sized pharmaceutical companies just starting out in the analytics space. Here’s what they had to say. 1. Start Small Before the emigration to a sophisticated analytics platform, it helps […]